CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 81 enrolled
Drug / intervention
Melatonindrug
Likely dose
Melatonin 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01690000
NCT01690000N/ACompleted
CompareCT.gov

Treatment of Osteopenia With Melatonin: Effects on BMD, Muscle Strength and Quality of Life

University of Aarhus·interventional·Posted Sep 21, 2012·Updated May 6, 2016

In Brief

A clinical study evaluating Melatonin for Osteoporosis. Completed, enrolled 81 participants across 1 site.

Detailed Summary

The aim of the study is to assess the effect of melatonin treatment in patients with osteopenia on BMD, muscle function, quality of life and calcium homeostasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 21, 2012
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.8 years ago

Interventions

Melatonindrug

1 or 3 mg of melatonin PO each night for 12 months